FDA Updates Afrezza Label with Clearer Dose Guidance for Insulin Transition
Event summary
- FDA approved an update to Afrezza's Prescribing Information on January 26, 2026, providing clearer starting dose guidance for patients switching from subcutaneous mealtime insulin regimens.
- The update is based on modeling data and in vivo results from the Dose Optimization study and the INHALE-3 trial, demonstrating improved postprandial glucose outcomes.
- The revised dosing recommendations include a table for converting from injected mealtime insulin or insulin pump bolus dosing to the appropriate mealtime dosage of Afrezza.
- Afrezza remains the only ultra-rapid-acting inhaled insulin approved by the FDA for improving glycemic control in adult patients with diabetes mellitus.
The big picture
The FDA's approval of the updated Afrezza label comes at a time when the diabetes treatment landscape is increasingly focused on patient-centric solutions. This update aligns with broader industry trends towards personalized medicine and simplified insulin regimens. MannKind's ability to provide clearer dosing guidance could enhance Afrezza's appeal to both healthcare providers and patients, potentially expanding its market share in the cardiometabolic space.
What we're watching
- Adoption Dynamics
- How the updated dosing guidance will affect healthcare provider adoption of Afrezza for patients transitioning from subcutaneous insulin.
- Clinical Impact
- Whether the improved postprandial glucose outcomes will translate into better long-term glycemic control for Afrezza users.
- Competitive Positioning
- The pace at which MannKind can leverage this update to differentiate Afrezza in the crowded diabetes treatment market.
Related topics